Your fact-checks will appear here
The treatment of type 2 diabetes using chromium and alpha-lipoic acid.
A broad, evidence-based arsenal of FDA‑approved therapies exists for type 2 diabetes: lifestyle plus metformin remains the long‑standing first‑line approach, and pharmacologic options now include mult...
Metformin, GLP‑1 receptor agonists (GLP‑1RAs) and SGLT2 inhibitors all lower A1C but differ in magnitude and persistence: metformin provides modest, durable reductions and remains first‑line; GLP‑1RAs...
Randomized clinical trials of chromium and alpha‑lipoic acid (ALA) have been conducted for decades, but the literature is mixed: multiple RCTs and meta‑analyses exist showing small or inconsistent eff...
Randomized controlled trials exist that directly compare berberine combined with metformin versus metformin alone, mostly small, short-duration studies conducted in China and pooled in recent meta-ana...
Bydureon (exenatide extended‑release) is a once‑weekly injectable GLP‑1 receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes in adults and certai...